Xencor to Participate at Upcoming Investor Conferences

Audio By Carbonatix

PASADENA, Calif.--(BUSINESS WIRE)--Nov 10, 2025--

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences:

• TD Cowen Immunology and Inflammation Virtual Summit
  Date: Wednesday, November 12, 2025
  Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT

• Piper Sandler 37th Annual Healthcare Conference
  Date: Tuesday, December 2, 2025
  Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT

Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251110946225/en/

CONTACT: Charles Liles

[email protected]

(626) 737-8118

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Xencor, Inc.

Copyright Business Wire 2025.

PUB: 11/10/2025 04:01 PM/DISC: 11/10/2025 04:01 PM

http://www.businesswire.com/news/home/20251110946225/en